Priority Voucher Awarded to Leadiant Bioscience

Federal Register notice: FDA has awarded a priority review voucher to Leadiant Bioscience after determining that rare disease drug Revcovi (elapegademase-lvlr) injection meets the award criteria. The product is approved for treating adenosine deaminase-severe combined immunodeficiency in pediatric and adult patients. To view the notice, click here.

Read more